-+ 0.00%
-+ 0.00%
-+ 0.00%

CSPC says FDA clears US clinical trial for SYS 6037 mpox mRNA vaccine

PUBT·08/10/2026 10:58:01
Listen to the news
CSPC says FDA clears US clinical trial for SYS 6037 mpox mRNA vaccine
  • CSPC’s SYS 6037 injection, an mRNA monkeypox vaccine co-developed with the Chinese Academy of Sciences’ Institute of Microbiology, cleared FDA review to start US clinical trials.
  • The US trial authorization advances CSPC’s mRNA vaccine pipeline, with the company citing potential cost and manufacturing-control advantages for the single-strand, multi-antigen design.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260810-12278930), on August 10, 2026, and is solely responsible for the information contained therein.